Table 1.

Nomination of candidate PARPi combination therapies based on identified molecular processes and existing small molecular drugs with clinical relevance

Molecular process	Target	Drug combination with PARPi
Lipid metabolism	FASN	PARPi + TVB-2640
NF-κB signaling	IκBα	PARPi + Bortezomib
Cell proliferation	ElF5A-2	PARPi + N(1)-guanyl-1,7,-diamineohephane (GC7)
Mitotic exit	UBE2S/APC/C	PARPi + proTAME